Skip to main content
2024 AABB Annual Meeting Main banner
Icon Legend
This session is not in your favorites.
This session is in your favorites. Click again to remove it.
Presentation Icons
Live Stream Sessions
Live Stream Sessions
Video

Public Health, Policy and Ethics

Oral Abstract - COVID

Saturday, October 19, 2024
1:45 PM - 2:45 PM  
Location: 342
CE: 0 CME (AMA Physician Credit) / 1 CE (Non-Physician Credit)

    Program Chair(s)

  • Mike Busch, MD, PhD (he/him/his)

    Director Emeritus
    Vitalant Research Institute
    San Francisco, California, United States

    Disclosure(s): Abbott: Stock Shareholder (self-managed) (Ongoing); Grifols Diagnostic Solutions: Grant/Research Support (Ongoing); Hologic: Grant/Research Support (Ongoing); International Society of Blood Transfusion: Consultant/Advisory Board (Ongoing), Immediate Past Present; Board of Directors (Ongoing); QuidelOrtho: Grant/Research Support (Terminated); Vitalant: Full-time/Part-time Employee or Owner (Ongoing)

    PDF

  • Freddy Nguyen, MD, PhD

    CEO, Co-Founder - Nine Diagnostics
    Fellow - MIT

    Disclosure information not submitted.

Disclosure(s):
Mike Busch, MD, PhD: Abbott: Stock Shareholder (self-managed) (Ongoing); Grifols Diagnostic Solutions: Grant/Research Support (Ongoing); Hologic: Grant/Research Support (Ongoing); International Society of Blood Transfusion: Consultant/Advisory Board (Ongoing), Immediate Past Present; Board of Directors (Ongoing); QuidelOrtho: Grant/Research Support (Terminated); Vitalant: Full-time/Part-time Employee or Owner (Ongoing)

Learning Objectives:

  • Understanding the role of representative populations and seroprevalence in study design and surveillance studies to determine its applicability for the larger population.
  • Determining the role of prior SARS-CoV-2 Infection and Vaccination status of blood donors on the rate of transfusion reactions in recipients without COVID-19.
  • Evaluating the use of Fresh Frozen Plasma as an additional option to high titer COVID-19 Convalescent Plasma based on SARS-CoV-2 IgG Antibodies levels.
  • Understanding the impact of the COVID-19 Pandemic on the blood donor demographics and blood supply, and the ability to meet the blood product needs in the United States.

Presentations:

  • 1:45 PM - 2:45 PM  
    Assessing Comparability of Canadian SARS-CoV-2 Serological Surveillance Studies While Adjusting for Representativeness

    Presenting Author: W. Alton Russell, PhD (he/him/his) – McGill School of Population and Global Health

  • 1:45 PM - 2:45 PM  
    Blood donor SARS-CoV-2 Infection and Vaccination is not Associated with Adverse Outcomes in Plasma and Platelet Transfusion Recipients Without Acute COVID-19

    Presenting Author: Nareg Roubinian, MD, MPHTM – Kaiser Permanente Northern California Division of Research

  • 1:45 PM - 2:45 PM  
    Comparison of SARS-CoV-2 IgG Antibodies between Convalescent Plasma and Conventional Plasma Units

    Presenting Author: Andrew Sulaiman, DO, PhD (he/him/his) – Johns Hopkins University

  • 1:45 PM - 2:45 PM  
    Evolving Blood Donor Demographics in the United States During the COVID-19 Pandemic

    Presenting Author: W. Alton Russell, PhD (he/him/his) – McGill School of Population and Global Health